The effect of sodium‐glucose cotransporter 2 inhibitors on HbA1c variability and cardiovascular and renal adverse outcome in patients with T2DM

Documenti analoghi

• Association of initial serum sodium change and clinical outcome in patients with diabetes receiving sodium–glucose cotransporter‐2 inhibitor therapy: A multicentre database analysis in Taiwan
  di: Yu‐Wen Cheng, et al.
  Pubblicazione: (2024)
• Revisiting peri‐operative cessation of sodium‐glucose cotransporter‐2 inhibitors: time for risk‐based individualisation?
  di: Ching‐Yuan Yeh, et al.
  Pubblicazione: (2025)
• Clinical use and monitoring of adverse effects of sodium‐glucose cotransporter‐2 inhibitors in persons with type 1 diabetes mellitus
  di: Chinatsu Sakai, et al.
  Pubblicazione: (2025)
• Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia
  di: Yuri Sakai Ishizaki, et al.
  Pubblicazione: (2024)
• Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors in the treatment of diabetic nephropathy in Japan
  di: Keiko Maruyama‐Sakurai, et al.
  Pubblicazione: (2024)